SG Americas Securities’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-34,073
| Closed | -$167K | – | 3996 |
|
|
2021
Q3 | $167K | Sell |
34,073
-42
| -0.1% | -$204 | ﹤0.01% | 3347 |
|
|
2021
Q2 | $180K | Hold |
34,115
| – | – | ﹤0.01% | 2387 |
|
|
2021
Q1 | $164K | Sell |
34,115
-100
| -0.3% | -$522 | ﹤0.01% | 2808 |
|
|
2020
Q4 | $148K | Hold |
34,215
| – | – | ﹤0.01% | 2819 |
|
|
2020
Q3 | $141K | Sell |
34,215
-1,000
| -3% | -$3.87K | ﹤0.01% | 2313 |
|
|
2020
Q2 | $90K | Sell |
35,215
-8,433
| -19% | -$24.8K | ﹤0.01% | 3420 |
|
|
2020
Q1 | $126K | Buy |
43,648
+3,857
| +10% | +$17.3K | ﹤0.01% | 2825 |
|
|
2019
Q4 | $151K | Buy |
39,791
+3,077
| +8% | +$14.7K | ﹤0.01% | 2689 |
|
|
2019
Q3 | $188K | Buy |
+36,714
| New | +$227K | ﹤0.01% | 2387 |
|
|
2019
Q2 | – | Sell |
-33,766
| Closed | -$240K | – | 3565 |
|
|
2019
Q1 | $240K | Buy |
33,766
+9,213
| +38% | +$82.8K | ﹤0.01% | 2439 |
|
|
2018
Q4 | $210K | Buy |
+24,553
| New | +$319K | ﹤0.01% | 2361 |
|
|
2017
Q4 | – | Sell |
-5,202
| Closed | -$110K | – | 3786 |
|
|
2017
Q3 | $110K | Buy |
+5,202
| New | +$95.4K | ﹤0.01% | 3131 |
|
|
2017
Q1 | – | Sell |
-8,445
| Closed | -$143K | – | 3652 |
|
|
2016
Q4 | $143K | Buy |
+8,445
| New | +$131K | ﹤0.01% | 2612 |
|
SG Americas Securities's ADMS Position: Q4 2021 in Review
SG Americas Securities sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 34,073 shares — an estimated $167K sold.
SG Americas Securities first reported a position in ADMS in Q4 2016 and held it in 13 quarters. The position peaked at $240K in Q1 2019. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- SG Americas Securities reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- SG Americas Securities sold 34,073 Adamas Pharmaceuticals shares in Q4 2021, an estimated $167K.
- SG Americas Securities first reported a position in Adamas Pharmaceuticals in Q4 2016 and held it in 13 quarters.
- SG Americas Securities's Adamas Pharmaceuticals position peaked at $240K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on SG Americas Securities's 13F filing for Q4 2021, filed 7 Feb 2022.